BENEFITS OF METRONOMIC THERAPY TARGETING MUSCARINIC RECEPTORS IN BREAST CANCER AS A SENSITIZER OF CELLS TO CLASSIC CHEMOTHERAPY WITH PACLITAXEL

YAMILA SANCHEZ; LUCAS LASERNA; ALEJANDRO ESPAÑOL; MARIA ELENA SALES; AGUSTINA SALEM; MARTIN WILLIAMS

Buenos Aires

Congreso; LXII Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2017

SAIC-SAI-SAFE-SAFIS-SAIB-SAA-SAB-SAB-SHA-SAP.

Abstract: Resistance to chemotherapy is a critical problem in cancer treatment and is believed to be due to the presence of a sub-population of cells named cancer stem cells (CSC). It has been postulated that metronomic therapy (administration of low doses of drugs with short inter-dose intervals) could be a useful strategy to over-come the resistance to traditional chemotherapeutic regimens. Here, we analyzed the effect of a combination of subthreshold concentrations of carbachol (CARB) (10-11M) with paclitaxel (PX) (10-9M) on MCF-7 breast cells, derived from a human luminal tumor. The unique addition of the combination during 40 h increased cell death by 47±6 % (p